Cardiovascular diseases are the leading cause of illness and death worldwide, responsible for c 31% of all global deaths.. Previously, assessment of the disease risk was based on the lifestyle of an individual. The role of genetic testing is now becoming increasingly important. Genetic testing can detect the underlying condition, provide a prognosis and identify at-risk family members, who might be predisposed to the same cardiovascular disease. Identification of a genetic mutation that causes a disease, can lead to an improved prognosis as well as eective clinical management and treatment for many cardiovascular conditions.
Ventrilia is a new generation genetic test that analyzes 292 genes to detect mutations that cause multiple cardiovascular conditions with complex phenotypes. By identifying genetic mutations that could cause cardiovascular diseases, Ventrilia can provide you with comprehensive genetic insight about your patient’s cardiovascular health and guide you towards an optimal clinical management plan.
The Cardiovascular Panel Tests can be used to:
Identify the genetic variant in symptomatic individuals with a clinically diagnosed cardiovascular condition
Identify the genetic variant in presymptomatic individuals with a clinically diagnosed cardiovascular condition
Identify the genetic variant in asymptomatic individuals that belong in high-risk groups
Ventrilia tests for autosomal recessive, autosomal dominant and X-linked cardiovascular diseases.
Assessment of clinically actionable mutations
Superior targeted genomic analysis
Easy to interpret results
Competitive turn-around time
Informed clinical management
Non-Invasive sample collection i.e by oral brushing.
For more information contact DNA Consulta on 2145 6711 or 7979 7910 or send an email to email@example.com